Over the years, the treatment of metabolic disorders has proven successful. Type 2 diabetes progressed irrespective of the approaches used to treat it, and hence people with obesity-related complications had to suffer due to a lack of appropriate treatment of metabolic disorders. Furthermore, despite the great efforts of modern pharmacology, patients suffering from metabolic syndrome and obesity remained at a high risk of cardiovascular diseases.
Key Takeaways
|
What Metabolic Health Is and Why It Has Become a Defining Health Challenge
Metabolic health refers to the functionality of systems that regulate blood sugar levels, blood pressure, levels of blood fats, body weight, and inflammation. When these systems function normally, the risk of type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, and kidney damage is associated with only small risks. However, when just one metabolic process becomes dysfunctional, the aforementioned pathologies do not appear separately but all at once, resulting in overlapping complications that cannot be addressed by any single treatment.
Over the last few decades, metabolic dysfunction has been steadily rising across the globe. The number of adults with type 2 diabetes has exceeded 500 million; the number of overweight and obese adults has more than doubled since 1990; and the so-called metabolic syndrome, characterised by abdominal obesity, elevated blood sugar levels, elevated blood pressure, and abnormal blood fat levels, has occurred in almost a quarter of adult populations in developed countries. All this creates enormous demand for effective medication.
How GLP-1 Medicines Approached the Problem Differently
GLP-1 medications operate using a hormonal mechanism that affects many systems in the body as opposed to one type of metabolism. It works by influencing GLP-1 receptors found in the pancreas, brain, intestines, heart, and kidneys, leading to a complex body reaction that leads to reduced appetite, slowed digestion, stabilisation of blood sugar levels, reduction of blood pressure, decrease in inflammation, and relaxation of some organs suffering from excess stress caused by metabolism. This extensive action distinguishes GLP-1 medications from other diabetes treatments. While previous treatment methods targeted one issue, GLP-1 receptor agonists address the primary cause instead of just treating symptoms.
The Cardiovascular Evidence That Changed the Field
The 2016 LEADER trial became the first to prove that GLP-1 receptor agonists decrease the probability of major adverse cardiovascular events in patients with type 2 diabetes with an increased risk of cardiac complications, which led to the amendments in regulatory recommendations advising patients with diagnosed cardiovascular disease to use GLP-1 agents for glycemic control regardless of their blood glucose levels.
Starting from the 2023 SELECT trial, the evidence base was expanded significantly as the trial results demonstrated a 20% fall in the incidence of cardiac events due to treatment with semaglutide in patients suffering from heart disease and obesity without type 2 diabetes, proving that the cardiovascular effect of GLP-1 medications is not influenced by their blood sugar parameters.
Kidney and Liver Benefits Emerging From Clinical Trials
Most recently, the FLOW study proved that semaglutide inhibits the advancement of renal disease and prevents kidney-related fatalities in patients with type 2 diabetes and chronic kidney disease. This extends the use of semaglutide to one more body system. Studies carried out on metabolic dysfunction-associated steatohepatitis - a chronic disease of the liver associated with obesity and insulin resistance- have shown good results in inhibiting liver inflammation and fibrosis, a disease that did not have any prior pharmacological treatment.
The Two Formulations That Have Defined Semaglutide's Reach
Semaglutide’s versatility manifests in different formulations that are approved for various indications and patient groups. Ozempic (Injection 1mg) is a weekly subcutaneous formulation of semaglutide that has been approved for the treatment of type 2 diabetes with a dosage of 1mg a week and is effective in blood sugar management and reducing cardiovascular risk.
Wegovy FlexTouch is a higher weekly dosage formulation of semaglutide that has been approved for weight management at a dose of up to 2.4mg per week and is delivered using a simple injection device. A trial performed under the STEP program has shown an average body weight loss of roughly 15% in patients who have been treated with this semaglutide formulation in 68 weeks.
What the Future of This Medicine Class Looks Like
Research into GLP-1-based therapy is far from complete. Several active areas of investigation are likely to further expand what these medicines can do:
- Combination agents are showing improved weight loss results in clinical trials, specifically due to the activation of GLP-1 as well as its additional hormonal pathways.
- Lighter dosing schedules are being developed through novel formulations that require only once-monthly delivery, which would reduce the burden for patients who normally need to administer an injection every week.
- Oral preparations are being developed at higher doses, which might allow for complete elimination of the need for injections.
- Efficacy of non-alcoholic and metabolic steatohepatitis medications is being studied through clinical trials, which may lead to the discovery of the first medical treatment for this condition.
Managing Side Effects During Treatment
The most common effects of GLP-1 treatment are connected with the gastrointestinal tract, with their severity being maximal at the start of treatment. Nausea, loose stools, and loss of appetite typically resolve after four to eight weeks. Other adverse effects are relatively rare but serious, including pancreatitis, which may affect some people, and concerns regarding thyroid C-cell tumors in patients with personal or family history of medullary thyroid cancer.
Importance of Follow-Up Care
If people continue to use GLP-1 therapy, they will keep getting metabolic benefits, but in order to do that, metabolic markers must be monitored continuously. The metabolic indicators that are monitored periodically include blood glucose, HbA1c, blood pressure, renal function, as well as weight. When metabolic parameters improve, the doses of other medications must be adjusted in order to avoid hypo- or over-treatment of hypertension. In reality, the benefits of medications become evident over months and years, not in weeks, so it is mandatory to remain in touch with the doctor prescribing the treatment from a long-term perspective.
What Is Worth Remembering
GLP-1 medicines have proven to be better diabetes medicines. Rather, they are an entirely new class of metabolic medication targeting the hormonal and physiological abnormalities behind a connected group of chronic illnesses affecting hundreds of millions of people worldwide. The wide range of benefits in blood sugar regulation, body weight control, cardiovascular risk, kidney function, and liver health is evidence of a fundamentally different approach to pharmacological treatment of metabolic diseases. The evidence is constantly accumulating, and the clinical applications are broadening.
Disclaimer: This article is for general informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or modifying any medication or treatment plan.
Sign in to leave a comment.